IGC Pharma, Inc.

Equities

IGC

US45408X3089

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.4 USD -1.60% Intraday chart for IGC Pharma, Inc. +17.65% +42.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law MT
Aurora Cannabis, Canopy Growth Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law MT
IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited CI
IGC Pharma, Inc Announces the Results of an Interim Analysis of its Ongoing Phase 2 Trial Investigating IGC-Ad1 as Treatment for Agitation in Dementia from Alzheimer?s Disease CI
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors CI
IGC Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
IGC Pharma Announces Tgr-63 Reduces Agitation in Alzheimer's Mouse Model CI
IGC Pharma, Inc. Provides Details on its Drug Candidate TGR-63 CI
Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer?S Trial CI
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's CI
IGC Pharma, Inc. Announces an Artificial Intelligence Collaboration with Los Andes University?s Center for Research and Training in Artificial Intelligence CI
IGC Pharma, Inc. Announces Master Agreement with University of Los Andes to Advance AI Initiatives CI
Earnings Flash (IGC) IGC PHARMA Posts Q2 Revenue $291,000 MT
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
IGC Pharma Receives European Patent for Cannabinoid Pain Treatment MT
North American Morning Briefing : Treasury Yields Keep Pushing Higher DJ
Earnings Flash (IGC) IGC PHARMA Reports Q1 Revenue $555,000 MT
IGC Pharma, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico CI
IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference CI
IGC Pharma, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
IGC Pharma, Inc. Enters into Master Loan and Security Agreement CI
IGC Pharma to Raise $3 Million in Gross Proceeds From Private Placement MT
IGC Pharma, Inc. announced that it expects to receive $3 million in funding CI
North American Morning Briefing : Stock Futures -2- DJ
Chart IGC Pharma, Inc.
More charts
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.4 USD
Average target price
3.25 USD
Spread / Average Target
+712.50%
Consensus
  1. Stock
  2. Equities
  3. Stock IGC Pharma, Inc. - Nyse
  4. News IGC Pharma, Inc.
  5. Earnings Flash (IGC) INDIA GLOBALIZATION CAPITAL Reports Q1 Revenue $212,000